313 related articles for article (PubMed ID: 11734230)
1. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
2. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
3. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients.
Huurman VA; Decochez K; Mathieu C; Cohen IR; Roep BO
Diabetes Metab Res Rev; 2007 May; 23(4):269-75. PubMed ID: 17024692
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
[TBL] [Abstract][Full Text] [Related]
5. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.
Huurman VA; van der Meide PE; Duinkerken G; Willemen S; Cohen IR; Elias D; Roep BO
Clin Exp Immunol; 2008 Jun; 152(3):488-97. PubMed ID: 18422727
[TBL] [Abstract][Full Text] [Related]
6. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
7. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens.
Elias D; Meilin A; Ablamunits V; Birk OS; Carmi P; Könen-Waisman S; Cohen IR
Diabetes; 1997 May; 46(5):758-64. PubMed ID: 9133541
[TBL] [Abstract][Full Text] [Related]
8. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells.
Birk OS; Elias D; Weiss AS; Rosen A; van-der Zee R; Walker MD; Cohen IR
J Autoimmun; 1996 Apr; 9(2):159-66. PubMed ID: 8738959
[TBL] [Abstract][Full Text] [Related]
9. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277.
Elias D; Cohen IR
Diabetes; 1995 Sep; 44(9):1132-8. PubMed ID: 7657040
[TBL] [Abstract][Full Text] [Related]
10. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Buzzetti R; Cernea S; Petrone A; Capizzi M; Spoletini M; Zampetti S; Guglielmi C; Venditti C; Pozzilli P;
Diabetes; 2011 Nov; 60(11):3067-72. PubMed ID: 21896927
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
12. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
Eldor R; Kassem S; Raz I
Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
[TBL] [Abstract][Full Text] [Related]
13. The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin.
Elias D; Cohen IR
Diabetes; 1996 Sep; 45(9):1168-72. PubMed ID: 8772717
[TBL] [Abstract][Full Text] [Related]
14. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes.
Elias D; Avron A; Tamir M; Raz I
Ann N Y Acad Sci; 2006 Oct; 1079():340-4. PubMed ID: 17130576
[TBL] [Abstract][Full Text] [Related]
15. DiaPep277® and immune intervention for treatment of type 1 diabetes.
Schloot NC; Cohen IR
Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
[TBL] [Abstract][Full Text] [Related]
16. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment.
Ablamunits V; Elias D; Reshef T; Cohen IR
J Autoimmun; 1998 Feb; 11(1):73-81. PubMed ID: 9480725
[TBL] [Abstract][Full Text] [Related]
17. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D; Fioriti E; Manfrini S; D'Amico E; Pozzilli P
Expert Opin Biol Ther; 2011 Sep; 11(9):1233-40. PubMed ID: 21751937
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update.
Fischer B; Elias D; Bretzel RG; Linn T
Expert Opin Biol Ther; 2010 Feb; 10(2):265-72. PubMed ID: 20034363
[TBL] [Abstract][Full Text] [Related]
19. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR; DiMeglio LA; Rendell MS; Felner EI; Dostou JM; Gitelman SE; Patel CM; Griffin KJ; Tsalikian E; Gottlieb PA; Greenbaum CJ; Sherry NA; Moore WV; Monzavi R; Willi SM; Raskin P; Moran A; Russell WE; Pinckney A; Keyes-Elstein L; Howell M; Aggarwal S; Lim N; Phippard D; Nepom GT; McNamara J; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):284-94. PubMed ID: 24622414
[TBL] [Abstract][Full Text] [Related]
20. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein.
Elias D; Marcus H; Reshef T; Ablamunits V; Cohen IR
Eur J Immunol; 1995 Oct; 25(10):2851-7. PubMed ID: 7589082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
